Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Mol Cancer Res. 2018 Jan 12;16(3):361–377. doi: 10.1158/1541-7786.MCR-17-0602

Figure 2. Cdk2 activity compensates for loss of cdk4 activity in PD resistant MCF7 cells.

Figure 2

(A) Proliferation of MCF7 cells treated with DMSO or PD. Media with DMSO or drug is refreshed every two days starting at day 2 (arrowhead). (B) Immunoblot analysis with treated MCF7 lysates. (N≥3). (C) Cdk4 activity [(RbS780/RB ratio)/cdk4] determined by densitometry (bottom) of in vitro kinase assay immunoblots (top) (N=5). (D) Cdk2 activity [(RbS7807/811/RB ratio)/cdk2] determined by densitometry (bottom) of in vitro kinase assay immunoblots in (top) (N=5). (E) p27 immunoprecipitated, followed by pY88 immunoblot (top). pY88/p27 ratio determined by densitometry (bottom) (N=3). (F) Cdk2 immunoprecipitated, followed by p27 immunoblot (top). p27 association with cdk2 determined by densitometry (bottom) (N=6).